D
12.29
-1.31 (-9.60%)
| Previous Close | 13.60 |
| Open | 13.59 |
| Volume | 2,888,124 |
| Avg. Volume (3M) | 1,123,258 |
| Market Cap | 1,784,692,480 |
| Price / Sales | 3.64 |
| Price / Book | 1.83 |
| 52 Weeks Range | |
| Earnings Date | 5 May 2025 - 9 May 2025 |
| Diluted EPS (TTM) | -2.57 |
| Total Debt/Equity (MRQ) | 4.42% |
| Current Ratio (MRQ) | 8.46 |
| Operating Cash Flow (TTM) | -347.69 M |
| Levered Free Cash Flow (TTM) | -208.83 M |
| Return on Assets (TTM) | -24.82% |
| Return on Equity (TTM) | -37.40% |
Market Trend
| Short Term | Medium Term | ||
| Industry | Biotechnology (US) | Mixed | Bearish |
| Biotechnology (Global) | Mixed | Bearish | |
| Stock | Denali Therapeutics Inc. | Bearish | Bearish |
AIStockmoo Score
2.3
| Analyst Consensus | 3.0 |
| Insider Activity | NA |
| Price Volatility | 3.0 |
| Technical Moving Averages | 2.5 |
| Technical Oscillators | 0.5 |
| Average | 2.25 |
|
Denali Therapeutics Inc is a biotechnology company that is engaged in developing and discovering therapeutics to defeat neurodegeneration disease. The company's development programs include the LRRK2 Inhibitor Program, which develops brain penetrant small molecule LRRK2 inhibitor product candidates for Parkinson's disease. Its key products include DNL201, DNL151, DNL747, ATV (Antibody Transport Vehicle), ETV (Enzyme Transport Vehicle), and others. |
|
| Sector | Healthcare |
| Industry | Biotechnology |
| Investment Style | Small Growth |
| % Held by Insiders | 9.56% |
| % Held by Institutions | 90.82% |
Ownership
| Name | Date | Shares Held |
|---|---|---|
| Crestline Management, Lp | 31 Dec 2024 | 4,310,732 |
| 52 Weeks Range | ||
| Price Target Range | ||
| High | 42.00 (Oppenheimer, 241.74%) | Buy |
| Median | 31.50 (156.31%) | |
| Low | 28.00 (B of A Securities, 127.83%) | Buy |
| Average | 32.50 (164.44%) | |
| Total | 8 Buy | |
| Avg. Price @ Call | 10.47 | |
| Firm | Date | Target Price | Call | Price @ Call |
|---|---|---|---|---|
| Baird | 08 May 2025 | 29.00 (135.96%) | Buy | 0.000 |
| HC Wainwright & Co. | 07 May 2025 | 32.00 (160.37%) | Buy | 0.000 |
| 28 Feb 2025 | 87.00 (607.89%) | Buy | 16.56 | |
| Wedbush | 07 May 2025 | 30.00 (144.10%) | Buy | 0.000 |
| B of A Securities | 10 Mar 2025 | 28.00 (127.83%) | Buy | 14.95 |
| Morgan Stanley | 07 Mar 2025 | 33.00 (168.51%) | Buy | 16.69 |
| B. Riley Securities | 05 Mar 2025 | 35.00 (184.78%) | Buy | 16.30 |
| Oppenheimer | 03 Mar 2025 | 42.00 (241.74%) | Buy | 15.20 |
| Deutsche Bank | 11 Feb 2025 | 31.00 (152.24%) | Buy | 20.58 |
No data within this time range.
The support, resistance and trendline levels presented has been generated by an artificial intelligence (AI) model and should be interpreted with caution.
Portfolio
| Realized Profit | - |
| Unrealized Profit | - |
| Dividend Received 2025 | - |
| Total Profit | - |
| Avg. Return | - |
| Quantity (Buy) | - |
| Avg. Price (Buy) | - |
| Quantity (Sold) | - |
| Avg. Price (Sold) | - |